Equities Analysts Offer Predictions for VERA Q2 Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA) – Equities research analysts at HC Wainwright cut their Q2 2026 earnings per share estimates for shares of Vera Therapeutics in a report released on Tuesday, May 12th. HC Wainwright analyst A. He now anticipates that the company will post earnings per share of ($1.70) for the quarter, down from their prior estimate of ($1.31). HC Wainwright has a “Buy” rating and a $110.00 price target on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($5.74) per share. HC Wainwright also issued estimates for Vera Therapeutics’ Q3 2026 earnings at ($1.57) EPS, Q4 2026 earnings at ($1.17) EPS, FY2026 earnings at ($6.13) EPS, FY2027 earnings at ($2.08) EPS, FY2028 earnings at $2.20 EPS, FY2029 earnings at $9.11 EPS and FY2030 earnings at $10.83 EPS.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same period in the prior year, the company earned ($0.81) earnings per share.

A number of other equities research analysts have also issued reports on VERA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. Wolfe Research upgraded Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price target for the company in a research note on Wednesday, March 11th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.60.

Vera Therapeutics Trading Up 6.7%

Shares of VERA stock opened at $39.15 on Thursday. Vera Therapeutics has a 52-week low of $18.76 and a 52-week high of $56.05. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. The firm has a market capitalization of $2.79 billion, a PE ratio of -7.07 and a beta of 0.96. The stock has a fifty day simple moving average of $39.63 and a two-hundred day simple moving average of $40.56.

Insider Activity

In related news, insider William D. Turner sold 2,187 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $91,810.26. Following the completion of the transaction, the insider owned 45,313 shares of the company’s stock, valued at $1,902,239.74. The trade was a 4.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Sean Grant sold 4,949 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $207,759.02. Following the completion of the transaction, the chief financial officer directly owned 114,181 shares of the company’s stock, valued at $4,793,318.38. This trade represents a 4.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 74,941 shares of company stock valued at $3,096,592. Insiders own 15.90% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

Large investors have recently bought and sold shares of the business. GAMMA Investing LLC grew its holdings in Vera Therapeutics by 50.5% in the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after purchasing an additional 236 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in Vera Therapeutics in the fourth quarter valued at $46,000. Quantbot Technologies LP purchased a new stake in Vera Therapeutics in the second quarter valued at $51,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Vera Therapeutics in the fourth quarter worth about $71,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Vera Therapeutics by 192.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after acquiring an additional 2,757 shares in the last quarter. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.